[go: up one dir, main page]

AR131922A2 - Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal - Google Patents

Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal

Info

Publication number
AR131922A2
AR131922A2 ARP240100410A ARP240100410A AR131922A2 AR 131922 A2 AR131922 A2 AR 131922A2 AR P240100410 A ARP240100410 A AR P240100410A AR P240100410 A ARP240100410 A AR P240100410A AR 131922 A2 AR131922 A2 AR 131922A2
Authority
AR
Argentina
Prior art keywords
polypeptides
disease
detection
methods
seq
Prior art date
Application number
ARP240100410A
Other languages
English (en)
Inventor
Mahalakshmi Yerramilli
Giosi Farace
John Joseph Quinn
Murthy V S N Yerramilli
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Publication of AR131922A2 publication Critical patent/AR131922A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/348—Urinary tract infections
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

La divulgación proporciona composiciones y métodos para la detección de enfermedad renal y enfermedad periodontal en mamíferos. Reivindicación 1: Uno o más polipéptidos no naturales aislados caracterizados porque consisten en SEQ ID Nº 2, 3, 5, 6, 7, 11 o 12. Reivindicación 2: Los uno o más polipéptidos no naturales aislados de la reivindicación 1, caracterizados porque los polipéptidos son: (a) liofilizados, desecados o secados; (b) conjugados con una etiqueta; (c) inmovilizados a un soporte sólido; (d) ligados específicamente a uno o más anticuerpos que se unen específicamente a uno o más polipéptidos expuestos en SEQ ID Nº 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 o 27. Reivindicación 3: Un inmunocomplejo caracterizado porque comprende (i) uno o más anticuerpos aislados que se unen específicamente a uno o más polipéptidos que consisten en SEQ ID Nº 1, 2, 3, 5, 6, 7, 11 o 12, y (ii) uno o más polipéptidos que se unen específicamente a los uno o más anticuerpos aislados. Reivindicación 4: El inmunocomplejo de la reivindicación 3, caracterizado porque el inmunocomplejo es inmovilizado a un soporte sólido.
ARP240100410A 2016-03-02 2024-02-22 Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal AR131922A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662302299P 2016-03-02 2016-03-02

Publications (1)

Publication Number Publication Date
AR131922A2 true AR131922A2 (es) 2025-05-14

Family

ID=58410448

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP170100523A AR107786A1 (es) 2016-03-02 2017-03-02 Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
ARP240100410A AR131922A2 (es) 2016-03-02 2024-02-22 Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP170100523A AR107786A1 (es) 2016-03-02 2017-03-02 Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal

Country Status (16)

Country Link
US (3) US10725052B2 (es)
EP (2) EP4299586A3 (es)
JP (3) JP7187317B2 (es)
KR (2) KR102311590B1 (es)
CN (1) CN108700600B (es)
AR (2) AR107786A1 (es)
AU (1) AU2017225758B2 (es)
BR (1) BR112018067292A2 (es)
CA (1) CA3016163A1 (es)
DK (1) DK3423838T5 (es)
ES (1) ES2970868T3 (es)
MX (2) MX2018010536A (es)
NZ (1) NZ745263A (es)
TW (1) TWI822655B (es)
WO (1) WO2017151871A1 (es)
ZA (1) ZA201806418B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI822655B (zh) * 2016-03-02 2023-11-21 美商英代斯實驗公司 用於檢測及診斷腎臟疾病及牙周病之方法及組合物
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
JP7207585B2 (ja) * 2017-09-01 2023-01-18 株式会社三洋物産 遊技機
CN110938130B (zh) * 2019-11-08 2021-07-09 上海交通大学 一种生物活性多肽rvfqplphenkpltl及其制备方法和应用
WO2021211969A2 (en) 2020-04-17 2021-10-21 Idexx Laboratories, Inc. Fluorescence quenching immunossay
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機
AU2023213987A1 (en) * 2022-01-26 2024-09-05 Idexx Laboratories, Inc. Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease
TWI882593B (zh) * 2022-12-23 2025-05-01 高雄醫學大學 上泌尿道結石風險評估模型建立方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5726010A (en) 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
NL1020962C2 (nl) 2002-06-28 2003-12-30 Tno Therapie en prognose/monitoring bij sepsis en septische shock.
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
US20070087448A1 (en) 2004-02-16 2007-04-19 Nelsestuen Gary L Biological profiles and methods of use
DE602006018578D1 (de) * 2005-01-28 2011-01-13 Childrens Medical Center Diagnose- und prognoseverfahren von blasenkrebs.
AU2006210794A1 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2007013575A2 (en) 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CN101120904B (zh) 2006-11-13 2011-06-29 李复生 癌症疾病治疗器
EP2535718B1 (en) 2007-05-11 2014-07-09 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
WO2010040029A1 (en) * 2008-10-02 2010-04-08 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
WO2010057184A2 (en) * 2008-11-17 2010-05-20 The Brigham And Women's Hospital, Inc. Methods for detection of acute kidney injury in humans
BR112012015693A8 (pt) 2009-12-23 2018-06-26 Hills Pet Nutrition Inc métodos para diagnosticar uma doença renal em um canino, para tratar melhorar ou atrasar a progressão de uma doença renal, sonda de ácido nucléico, e, uso de uma sonda
KR101222437B1 (ko) * 2010-03-17 2013-01-15 경북대학교 산학협력단 바이오마커
US10436797B2 (en) * 2010-06-03 2019-10-08 Idexx Laboratories, Inc. Markers for renal disease
CN101937000A (zh) * 2010-08-05 2011-01-05 北京倍爱康生物技术有限公司 一种人胱抑素c的磁微粒分离化学发光免疫分析检测方法
TWI822655B (zh) * 2016-03-02 2023-11-21 美商英代斯實驗公司 用於檢測及診斷腎臟疾病及牙周病之方法及組合物

Also Published As

Publication number Publication date
AU2017225758B2 (en) 2023-03-16
EP4299586A3 (en) 2024-04-03
WO2017151871A1 (en) 2017-09-08
US12385927B2 (en) 2025-08-12
KR20180114936A (ko) 2018-10-19
EP4299586A2 (en) 2024-01-03
TWI822655B (zh) 2023-11-21
JP7187317B2 (ja) 2022-12-12
AR107786A1 (es) 2018-06-06
MX2023012628A (es) 2023-11-08
CA3016163A1 (en) 2017-09-08
US20170269101A1 (en) 2017-09-21
CN108700600B (zh) 2022-06-03
EP3423838A1 (en) 2019-01-09
JP2022028790A (ja) 2022-02-16
EP3423838B1 (en) 2023-11-08
KR102311590B1 (ko) 2021-10-12
BR112018067292A2 (pt) 2019-01-02
ES2970868T3 (es) 2024-05-31
NZ745263A (en) 2022-07-01
CN108700600A (zh) 2018-10-23
JP7598843B2 (ja) 2024-12-12
JP2024028816A (ja) 2024-03-05
US20250341529A1 (en) 2025-11-06
DK3423838T3 (da) 2024-02-05
ZA201806418B (en) 2019-07-31
DK3423838T5 (da) 2024-09-16
TW201736850A (zh) 2017-10-16
KR102424496B1 (ko) 2022-07-25
US10725052B2 (en) 2020-07-28
JP2019508694A (ja) 2019-03-28
US20200400683A1 (en) 2020-12-24
KR20210127763A (ko) 2021-10-22
MX2018010536A (es) 2018-11-09
AU2017225758A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
AR131922A2 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
CO2018013471A2 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
MX2024014691A (es) Enlazadores de conjugacion mejorados
MX2020008184A (es) Receptores de antigeno quimericos dirigidos a cd70.
CR20240116A (es) RECEPTORES QUIMÉRICOS DE FLT3 Y MÉTODOS DE USO DE LOS MISMOS (Divisional 2018-518)
CO6700829A2 (es) Moduladores novedosos y métodos de uso
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PE20191708A1 (es) ANTICUERPOS DE UNION A VISTA A pH ACIDO
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
AR101844A1 (es) Anticuerpos y conjugados modificados genéticamente con cisteína
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
PE20150023A1 (es) Proteinas de union a antigeno st2
MX2017003565A (es) Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes.
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX389823B (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
AR070168A1 (es) Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos
CL2012002328A1 (es) Anticuerpo aislado anti-tat419 que inhibe la proliferación celular; ácido nucleico que lo codifica; célula que lo produce; método para identificar anticuerpos que unen un epítopo antigénico tat419; método para inhibir la proliferación de una célula que expresa un péptido tat419; y su uso en el tratamiento de tumores cancerígenos.
AR090510A1 (es) Anticuerpos anti-idiotipicos que se unen a anticuerpos contra el citomegalovirus humano (ab anti-hcmv), metodos de deteccion de los mismos y kit de inmunoensayo
MX2018013306A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos